Consensus Barinthus Biotherapeutics plc

Equities

BRNS

US91864C1071

Market Closed - Nasdaq Other stock markets 02:00:01 07/05/2024 am IST			5-day change	1st Jan Change
2.21 ^USD	+1.38%		-14.67%	-40.11%

01/05	Barinthus Biotherapeutics plc Appoints Leon Hooftman as Chief Medical Officer, Effective from Beginning of June 2024	CI
18/04	Barinthus Cervical Lesions Treatment Study Meets Primary Objective -- Shares Rise After Hours	MT

Evolution of the average Target Price on Barinthus Biotherapeutics plc

Price target over the last 5 years

History of analyst recommendation changes

fb3ee6b11026718d0.cLu8zMpYCtfUkthgv8nTVlG-VltutsO2rjve8_8l18Y.FdfVnrJrXLqS26Ax6r-SOxuIAAkn2u7j1lnsgZZCo7QE1smgi2pT5rzHgQ~e23115c0654f63389536561e31ea69e8

Analyst Recommendations on Barinthus Biotherapeutics plc

Vaccitech Shares Rise After Alliance Global Partners Begins Coverage With Buy Rating	26/23/26	MT
Alliance Global Partners Initiates Coverage on Vaccitech with Buy Rating, $12 Price Target	25/23/25	MT
Morgan Stanley Downgrades Vaccitech to Equal Weight From Overweight, Cuts Price Target to $3.25 From $14	25/23/25	MT
Morgan Stanley Adjusts Price Target on Vaccitech to $14 From $15, Maintains Overweight Rating	18/23/18	MT
Morgan Stanley Adjusts Price Target on Vaccitech to $15 From $16, Maintains Overweight Rating	16/23/16	MT
HC Wainwright Adjusts Price Target on Vaccitech to $15 From $20, Maintains Buy Rating	27/23/27	MT
Possibility of US Fed's Rate Hike Pause Supports American Depositary Receipts of European Equities	23/23/23	MT
Morgan Stanley Adjusts Price Target on Vaccitech to $16 From $19, Maintains Overweight Rating	15/22/15	MT
HC Wainwright Adjusts Vaccitech's Price Target to $20 From $22, Keeps Buy Rating	11/22/11	MT
Morgan Stanley Trims Vaccitech's Price Target to $19 From $20, Maintains Overweight Rating	17/22/17	MT
HC Wainwright Adjusts Price Target on Vaccitech to $23 From $25, Maintains Buy Rating	15/21/15	MT
VACCITECH : Barclays Initiates Coverage on Vaccitech With Overweight Rating, $23 Price Target	25/21/25	MT
VACCITECH : William Blair Initiates Coverage on Vaccitech With Outperform Rating	25/21/25	MT
VACCITECH : Morgan Stanley Starts Vaccitech at Overweight With $22 Price Target	25/21/25	MT
VACCITECH : Jefferies Starts Vaccitech at Buy With $28 Price Target	25/21/25	MT
VACCITECH : HC Wainwright Starts Vaccitech at Buy With $25 Price Target	24/21/24	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.18 USD

Average target price

7.4 USD

Spread / Average Target

+239.45%

High Price Target

12 USD

Spread / Highest target

+450.46%

Low Price Target

3 USD

Spread / Lowest Target

+37.61%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Barinthus Biotherapeutics plc

Alliance Global Partners
Morgan Stanley
HC Wainwright
Jefferies & Co.
William Blair & Co.
Barclays

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar